The type I interferon system in idiopathic inflammatory myopathies

References

• Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, . Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA. 2000; 97 16: 9209–9214.
   Web of Science ®Google Scholar
• Salomonsson S, Grundtman C, Zhang SJ, Lanner JT, Li C, Katz A, Wedderburn LR, Nagaraju K, Lundberg IE, Westerblad H. Upregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle. Muscle Nerve. 2009; 39 5: 674–682.
   Google Scholar
• Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, . Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005; 57 5: 664–678.
   PubMed Web of Science ®Google Scholar
• Halloran PF, Urmson J, Van der Meide PH, Autenried P. Regulation of MHC expression in vivo. II. IFN-alpha/beta inducers and recombinant IFN-alpha modulate MHC antigen expression in mouse tissues. J Immunol. 1989; 142 12: 4241–4247.
   Google Scholar
• Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, Oberg K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Q J Med. 1998; 91 6: 393–399.
   Google Scholar
• Venezia G, Licata A, Di Marco V, Craxi A, Almasio PL. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. Dig Liver Dis. 2005; 37 11: 882–885.
   Google Scholar
• Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol (Northwood, London, England). 2000; 17 1: 64–69.
   Web of Science ®Google Scholar
• Somani AK, Swick AR, Cooper KD, McCormick TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol. 2008; 144 10: 1341–1349.
   PubMedGoogle Scholar
• Isenberg DA, Rowe D, Shearer M, Novick D, Beverley PC. Localization of interferons and interleukin 2 in polymyositis and muscular dystrophy. Clin Exp Immunol. 1986; 63 2: 450–458.
   Google Scholar
• Greenberg SA, Sanoudou D, Haslett JN, Kohane IS, Kunkel LM, Beggs AH, . Molecular profiles of inflammatory myopathies. Neurology. 2002; 59 8: 1170–1182.
   Google Scholar
• Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG, . Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: A novel model of pathogenesis. J Immunol. 2002; 168 8: 4154–4163.
   Google Scholar
• Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, . Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007; 56 11: 3784–3792.
   PubMed Web of Science ®Google Scholar
• Lopez de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB, . Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheumat. 2007; 56 5: 1658–1668.
   Google Scholar
• Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, . An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007; 13 1–2: 59–68.
   PubMed Web of Science ®Google Scholar
• Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, . Activation of the type I interferon system in primary Sjogren's syndrome: A possible etiopathogenic mechanism. Arthritis Rheum. 2005; 52 4: 1185–1195.
   PubMed Web of Science ®Google Scholar
• Lövgren T, Eloranta ML, Båve U, Alm GV, Rönnblom L. Induction of interferon-alpha production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and lupus IgG. Arthritis Rheum. 2004; 50 6: 1861–1872.
   PubMedGoogle Scholar
• Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, . A new approach to the classification of idiopathic inflammatory myopathy: Myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991; 70 6: 360–374.
   PubMed Web of Science ®Google Scholar
• Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007; 56 9: 3112–3124.
   PubMedGoogle Scholar
• Wenzel J, Schmidt R, Proelss J, Zahn S, Bieber T, Tuting T. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exper Dermatol. 2006; 31 4: 576–582.
   Google Scholar
• Krystufková O, Vallerskog T, Barbasso Helmers S, Mann H, Putová I, Belácek J, Malmström V, Trollmo C, Vencovsky J, Lundberg IE. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009; 68 6: 836–843.
   PubMed Web of Science ®Google Scholar
• Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, . Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity. 2004; 20 6: 785–798.
   PubMed Web of Science ®Google Scholar
• Litinskiy MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, . DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nature Immunol. 2002; 3 9: 822–829.
   PubMed Web of Science ®Google Scholar
• Barbasso Helmers S, Englund P, Engström M, Ahlin E, Fathi M, Janciauskiene S, Heimbürger M, Rönnelid J, Lundberg IE. Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum. 2009; 60 8: 2524–2530.
   Google Scholar
• Reefman E, Kuiper H, Limburg PC, Kallenberg CG, Bijl M. Type I interferons are involved in the development of UVB-induced inflammatory skin lesions in systemic lupus erythematosus (SLE) patients. Ann Rheum Dis. 2008; 67 1: 11–18.
   PubMed Web of Science ®Google Scholar
• Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, . A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008; 67 12: 1670–1677.
   PubMed Web of Science ®Google Scholar
• Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum. 2007; 56 12: 3995–4004.
   PubMedGoogle Scholar